Data gathered: February 23
AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated February 20, 2025. Powered by Chat GPT.
Gilead Sciences, Inc. is a leading biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide, including HIV/AIDS, liver diseases, cancer, and more. With a robust product portfolio and a pipeline encompassing various stages of development, Gilead is well-positioned in the biotechnology sector.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | February 20 Insider Alert: Dickinson Andrew D is selling shares |
|
Gilead Sciences | February 18 Business Outlook among employees is down by 3.5% over the last month. |
|
Gilead Sciences | February 14 Insider Alert: Dickinson Andrew D is continuing selling shares |
|
Gilead Sciences | February 12 Price is up by 5.7% in the last 24h. |
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $109.95 |
| Target Price | Sign up |
| Volume | 9,730,000 |
| Market Cap | $137B |
| Year Range | $62.05 - $110.03 |
| Dividend Yield | 2.87% |
| PE Ratio | 289.34 |
| Analyst Rating | 62% buy |
| Industry | Biotechnology |
In the news
Gilead Sciences Inc. stock outperforms competitors on strong trading dayFebruary 19 - MarketWatch |
|
Gilead Sciences to Present at Upcoming Investor ConferencesFebruary 19 - Finnhub |
|
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune DiseaseFebruary 18 - Finnhub |
|
 |
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?February 16 - Yahoo |
 |
Gilead Sciences, Inc. (GILD): A Bull Case TheoryFebruary 16 - Yahoo |
 |
Gilead Sciences (NASDAQ:GILD) Upgraded at DZ BankFebruary 16 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 7.54B | 4.79B | 2.76B | 1.25B | 0 | 2.020 |
| Q2 '24 | 6.98B | 2.94B | 4.04B | 1.61B | 0 | 2.010 |
| Q1 '24 | 6.46B | 5.42B | 1.04B | -4.17B | 0 | -1.320 |
| Q4 '23 | 6.87B | 5.08B | 1.79B | 1.43B | 2.52B | 1.720 |
| Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B | 2.290 |
Insider Transactions View All
| Dickinson Andrew D filed to sell 169,061 shares at $104.1. February 19 '25 |
| Dickinson Andrew D filed to sell 171,223 shares at $102.2. February 13 '25 |
| Dickinson Andrew D filed to sell 129,873 shares at $97.2. February 3 '25 |
| Dickinson Andrew D filed to sell 129,873 shares at $91.4. January 16 '25 |
| Dickinson Andrew D filed to sell 132,373 shares at $92. December 17 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Marjorie Taylor Greene |
Dec 30, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
May 15, 24 | Buy | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $137B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 289.34.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $109.95.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 2.87%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.